Advent Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Advent Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-195	Closed	-$10K	–	238
2019 Q2	$10K	Buy	+195	New	+$3.52K	﹤0.01%	195
2018 Q4	–	Sell	-425	Closed	-$361K	–	349
2018 Q3	$361K	Buy	425 +125	+42%	+$4.84K	0.01%	207
2018 Q2	$123K	Buy	+300	New	+$14.6K	﹤0.01%	234
2017 Q3	–	Sell	-55	Closed	-$1K	–	351
2017 Q2	$1K	Buy	+55	New	+$3.37K	﹤0.01%	301
2017 Q1	–	Sell	-150	Closed	-$2K	–	319
2016 Q4	$2K	Sell	150 -50	-25%	-$1.76K	﹤0.01%	300
2016 Q3	$6K	Buy	+200	New	+$4.29K	﹤0.01%	477
2016 Q2	–	Sell	-400	Closed	-$112K	–	495
2016 Q1	$112K	Sell	400 -450	-53%	-$9.52K	﹤0.01%	368
2015 Q4	$10K	Buy	+850	New	+$54.8K	﹤0.01%	429

Other funds holding CLVS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Advent Capital Management's CLVS Position: Q4 2018 in Review

Advent Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 5,000 shares — an estimated $147K sold.

Advent Capital Management first reported a position in CLVS in Q1 2016 and held it in 6 quarters. The position peaked at $1.76M in Q2 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

Advent Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
Advent Capital Management sold 5,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $147K.
Advent Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 6 quarters.
Advent Capital Management's Clovis Oncology, Inc. position peaked at $1.76M in Q2 2017.
165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Advent Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.